

1 **Delgocitinib cream reduces itch and pain in moderate to severe Chronic Hand Eczema:**
2 **Ph 3 DELTA 1 and 2 pooled analyses**

3 Andrea Bauer, MD¹, Marie-Louise Schuttelaar, PhD², Keith Baranowski, MD³, Ursula
4 Plohberger, MSc³, Laura Sørensen, MSc³, Margitta Worm, MD⁴

5 ¹ Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus,
6 Technical University Dresden, Dresden, Germany; ² University Medical Centre Groningen,
7 University of Groningen, Groningen, Netherlands; ³ LEO Pharma A/S, Ballerup, Denmark; ⁴
8 Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy,
9 Charité Universitätsmedizin Berlin, Berlin, Germany

10 **Corresponding author:**

11 Andrea Bauer, MD
12 Department of Dermatology,
13 University Allergy Center, University Hospital
14 Carl Gustav Carus, Technical University
15 Dresden, Dresden, Germany.
16 Telephone: +493514582497
17 Fax: +493514584338
18 Email: Andrea.Bauer@ukdd.de

Supplementary material

Plain language summary

Plain language summary title: Delgocitinib cream treatment up to 16 weeks reduced itch and pain in adults with moderate to severe Chronic Hand Eczema

Chronic Hand Eczema (CHE) is a skin disease characterized by itching and inflammation that causes pain.

Delgocitinib is a non-steroid cream that stops enzymes called Janus kinases that play a role in inflammation. The European Medicines Agency approved delgocitinib for treating moderate to severe CHE in adults for whom topical corticosteroids are inadequate or inappropriate.

We analysed the combined data from two Phase 3 (DELTA 1 and DELTA 2) trials. The aim of our analysis was to evaluate whether treatment with twice-daily delgocitinib cream 20 mg/g reduced the patients' levels of itch and pain compared with patients treated with a cream vehicle.

Our analysis included 960 adults with moderate to severe CHE who were treated with either delgocitinib cream or a cream vehicle for 16 weeks. Patients completed the Hand Eczema Symptom Diary every evening, to rate itch and pain levels they experienced during the past 24 hours on a numeric rating scale (0='no itch/pain' to 10='severe itch/pain').

A greater number of patients treated with delgocitinib cream experienced a meaningful reduction in both itch and pain when compared with a cream vehicle after one day of treatment for itch and three days for pain. These benefits and significant differences compared with the cream vehicle group were maintained throughout the 16 weeks of treatment. Treatment with delgocitinib cream was well tolerated.

Our results suggest that delgocitinib cream could provide early itch and pain relief (within one week) among patients with moderate to severe CHE.

43 **Table S1:** DELTA 1 and DELTA 2 independent ethics committee (IEC) / institutional review
 44 board (IRB) committee and trial investigators
 45 DELTA 1

IEC/IRB Committee Chair and Name of Committee	Investigator Site
Canada	
Chair: Dr Neil Malhotra, B.Sc. Phm, R.PH, CDE The Research Review Board Inc.	Dr Charles Lynde Lynderm Research Inc.
	Dr Lyn Guenther The Guenther Dermatology Research Centre
	Dr Maxwell Sauder Toronto Research Centre
	Dr Robert Bissonnette Innovaderm Research Inc
Chair: Dr Peter Venner, MD Chair - Health Research Ethics Board of Alberta	Dr Jaggi Rao RAO Dermatology
	Dr Isaiah Day CARE Clinic
	Dr Alim Devani Dermatology Research Institute Inc.
	Dr Andrei Metelitsa Beacon Dermatology Inc.
	Dr Parbeer Grewal Rejuvenation Laser Dermatology
Chair: Dr Dean Tripp, PhD Chair - Queen's University Health Sciences & Affiliated	Dr Sonja Molin Kingston Health Sciences Centre
France	
Chair: Pr Philippe Casassus Comité de Protection des Personnes (CPP) Ile-de-France X	Dr Mireille Ruer Mulard Cabinet médical du Dr Ruer
	Dr Françoise Giordano-Labadie CHU de Toulouse - Hopital Larrey
	Dr Hervé Maillard Centre Hospitalier du Mans
	Dr Ziad Reguai Clinique de Courlancy
	Dr Claire Bernier CHU de Nantes - Hôtel-Dieu
	Dr Camille Leleu CHU Dijon
	Dr Julien Seneschal Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospital Saint-Andre
	Dr Delphine Staumont-Sallé CHRU de Lille
	Dr Thomas Hubiche

IEC/IRB Committee Chair and Name of Committee	Investigator Site
	Hôpital de l'Archet, Dr Abdallah Khemis Cabinet Cideazur Tagast 41 Dr Marie Noelle Crepy Hopital Cochin - site Port Royal
Germany	
Chair: Prof Dr med K. Thomas Moesta Landesamt für Gesundheit und Soziales Berlin (LAGeSo)	Dr Margitta Worm Charité - Universitätsmedizin Berlin
Chair: PD Dr med Hermann Theilen Technische Universität Dresden	Dr Andrea Bauer Universitätsklinikum Carl Gustav Carus
Chair: PD Dr Friedrich Meier Landesärztekammer Thüringen	Dr Sabine Sell SRH Wald-Klinikum Gera GmbH
Chair: Prof Dr med Rolf Stahl Ärztekammer Hamburg	Dr Swarna Ekanayake-Bohli Mensingderma research GmbH
Chair: Prof Dr med Andreas Creutzig Ärztekammer Niedersachsen	Dr Sylvia Pauser KLIFOs Klinische Forschung Osnabrück
Chair: Prof Dr Jürgen Brockmöller Universitätsmedizin Göttingen	Dr Timo Buhl Universitätsmedizin Göttingen
Chair: PD Dr med Andreas Lechner Bayerischen Landesärztekammer	Dr Andreas Schwinn Beldio Research GmbH
Chair: Prof Dr Georg Schmidt Ethikkommission der Fakultät für Medizin der TU München	Dr Bernadette Eberlein TUM School of Medicine
Chair: Prof Dr med Dipl. Ing. Stephan Letzel Landesärztekammer Rheinland-Pfalz	Dr Sven Quist Dermatologie Dr. Jennifer Quist und Prof. Dr. Sven Quist
Chair: PD Dr med Andreas Lechner Bayerischen Landesärztekammer	Dr Boris Bauer Hautarztpraxis Haßberge
Italy	
Chair: Prof Andrea Bacigalupo Fondazione Policlinico Universitario Agostino Gemelli IRCCS – Università Cattolica del Sacro Cuore	Dr Ketty Peris Policlinico Universitario "Agostino Gemelli"
Chair: Prof Sandra Sigala, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Dr Maria Teresa Rossi ASST degli Spedali Civili di Brescia
Chair: Dr Goffredo Del Rosso Via Vetoio Località Coppito	Dr Maria Fagnoli Ospedale San Salvatore
Chair: Dr Paolo Pallini Viale Rodolfi, 37	Dr Luigi Naldi Ospedale San Bortolo, viale Rodolfi 37
Chair: Dr Caniglia Maurizio Ospedale S. Maria della Misericordia Piazzale Menghini	Dr Luca Stingeni Ospedale Santa Maria della Misericordia

IEC/IRB Committee Chair and Name of Committee	Investigator Site
Chair: Dr Gaetana Muserra, Fondazione IRCCS "Ca' Granda" Ospedale Maggiore Policlinico	Dr Silvia Ferrucci Fondazione IRCCS "Ca' Granda" Ospedale Maggiore Policlinico
Poland	
Chair: Prof Dr hab. n. med. Robert Gil Komisja Etyki i Nadzoru nad Badaniami na Ludziach i Zwierzętach przy CSK, MSWiA	Dr Irena Walecka-Herniczek CSK MSWiA, Oddział Dermatologii
Chair: Dr hab. n. med. Marcin Olajossy Komisja Bioetyczna przy Uniwersytecie, Medycznym w Lublinie	Dr Dorota Krasowska Samodzielny Publiczny Szpital Kliniczny nr 1, Klinika Dermatologii, Wenerologii I Dermatologii dziecięcej
Chair: Prof. Dr hab. n.med. Eugeniusz Małafiej Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Łodzi	Dr Aleksandra Lesiak Dermoklinika Centrum, Medyczne
Chair: Dr hab. n. med. Wojciech Makarewicz Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Gdańsku	Dr Aleksandra Okuniewska Centrum Badan Klinicznych PI-House SP.Z.O.O
Chair: Dr Mariusz Janikowski Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Krakowie	Dr Grażyna Pulka Centrum Medyczne All-med
	Dr Malgorzata Dyczek Centrum Nowoczesnych Terapii "Dobry Lekarz"
Chair: Dr hab. n. med. Marek Czarkowski Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Warszawie	Dr Bartłomiej Kwiek Klinika Ambroziak Sp. z o.o.
Chair: Prof Dr hab. med. Władysław Sinkiewicz Komisja Bioetyczna przy Bydgoskiej Izbie Lekarskiej	Dr Rafal Czajkowski DermaDent Centrum Medyczne Czajkowscy
Chair: Prof Dr hab. med. Włodzimierz Buczko Komisja Bioetyczna przy Okręgowej, Izbie Lekarskiej w Białymstoku	Dr Hanna Myśliwiec Renew Clinic Skórnicki Spółka Jawna
United Kingdom	
Chair: Dr Alan Lamont NHS Health Authority	Dr Padma Mohandas Whipps Cross Hospital
	Dr Sandeep Cliff East Surrey Hospital
	Dr Richard Warren Salford Royal Hospital
	Dr Pippa Cousen The James Cook University Hospital
	Dr Graham Johnston Leicester Royal Infirmary
	Dr Richard Woolf Guy's Hospital

46

47 DELTA 2


IEC/IRB Committee Chair and Name of Committee	Investigator Site
Canada	
IRB Chair: Mr. Neil Malhotra, B.Sc. Ph.M., R.PH, CDE Chair - Research Review Board Inc.	Dr. Kim Papp K. Papp Clinical Research
	Dr. David Adam CCA Medical Research
	Dr. Darryl Toth XLR8 Medical Research
	Dr. Chih-ho Hong Dr. Chih-ho Hong Medical Inc.
	Dr. Irina Turchin Dr. Irina Turchin PC Inc.
	Dr. Firouzeh Niakosari North York Research Inc.
	Dr. Elena Poulos Kingsway Clinical Research
	Dr. Jason Rivers Pacific Dermaesthetics
	Dr. Jason Ohayon Hamilton Allergy Clinic
	Dr. Melinda Gooderham Melinda Gooderham Professional Medicine Corporation
The Netherlands	
Dr. M.A. (Michel) Dutréé Bravis Ziekenhuis	Dr. Milan Tjioe Bravis Ziekenhuis
IRB Chair: Mrs Dr CL van der Wilt Kamer TKo-270	Dr. Thomas Rustemeyer Academic Medical Center
IRB Chair: METC NedMec	Dr. Marjolein de Bruin-Weller University Medical Centre Utrecht
IRB Chair: De Brug, Kamer 7.067	Dr. Marie Louise Schuttelaar University Medical Center Groningen
IRB Chair: dhr. O. (Olof) Suttorp (RVB) Prof. Dr. W.A.B. (Wim) Stalman (raad van commissarisse)	Dr. Judith Molhoek Amphia Ziekenhuis Breda
IRB Chair: Prof. Dr. I.N. (Ivo) van Schajk (RvB) Mr. B.B. (Bernt) Schneiders (RvT)	Dr. Bert Oosting Spaarne Hospital Hoofddorp
Germany	
IRB Chair: Prof. Dr. med. Sebastian Harder Fachbereichs Medizin Universitätsklinikum der Goethe-Universität	Dr. Andreas Pinter Klinikum der Johann Wolfgang Goethe- Universität Klinik Frankfurt am Main



IEC/IRB Committee Chair and Name of Committee	Investigator Site
IRB Chair: Prof. Dr. med. Andreas Creutzig Ärzttekammer Niedersachsen	Dr. Markus Kaspari Hautärzte Zentrum Hannover
IRB Chair: Prof. Dr. med. Wolfgang E. Berdel Ärzttekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster	Dr. Nina Magnolo Hauttumorzentrum des Universitätsklinikum Münster
IRB Chair: Prof. Dr. med. Hjalmar Steinhauer Landesärztekammer Brandenburg	Dr. Michael Sebastian Dr. Sebastian Hautarztpraxis Mahlow
IRB Chair: Prof. Dr. Alexander Katalinic Universität zu Lübeck	Dr. Diamant Thaci Exzellenzzentrum Entzündungsmedizin Universität zu Lübeck
IRB Chair: Prof. Dr. med. Ekkehard Schleußner Friedrich-Schiller-Universität Jena	Dr. Sibylle Schliemann Klinik für Hautkrankheiten Universitätsklinikum Jena
IRB Chair: Dr. med. Wolfgang Miller Landesärztekammer Baden-Württemberg	Dr. Peter Radny Derma-Study-Center Friedrichshafen GmbH
IRB Chair: Dr. med. Wolfgang Miller Landesärztekammer Baden-Württemberg	Dr. Nicolas Leitz Hautarztpraxis Dres
IRB Chair: Prof. Dr. med. Andreas Creutzig Ärzttekammer Niedersachsen	Dr. Athanasios Tsianakas Fachklinik Bad Bentheim
IRB Chair: Univ.-Prof. Dr. med. Dent. Dr. phil. Dominik Groß Rheinisch-Westfälischen Technischen Hochschule Aachen (RWTH Aachen)	Dr. Amir Yazdi Universitätsklinik RWTH Aachen
Denmark	
IRB Chair: Rene Mathiasen Pediatrics Rigshospitalet	Dr. Maria Kamstrup Bispebjerg Hospital
	Dr. Mette Sommerlund Department of Dermatology Aarhus University Hospital
	Dr. Claus Zachariae Gentofte Hospital
Poland	
IRB Chair: Prof. dr hab. n. med. Stanisław Niemczyk Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Warszawie	Dr. Witold Owczarek Royalderm Agnieszka Nawrocka
IRB Chair: Dr n. med. Janusz Dubejko Komisja Bioetyczna przy Lubelskiej Izbie Lekarskiej	Dr. Monika Dudra-Jastrzebska NZOZ Med-Laser Borzecki Spolka Jawna
IRB Chair: Dr hab. n. med. Andrzej Pluta Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Rzeszowie	Dr. Adam Reich Kliniczny Szpital Wojewódzki

IEC/IRB Committee Chair and Name of Committee	Investigator Site
IRB Chair: Prof. dr hab. n. med. Stanisław Niemczyk Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Warszawie	Dr. Elżbieta Kowalska- Oledzka Centrum Medyczne Evimed
IRB Chair: Dr n. med. Włodzimierz Bednorz Komisja Bioetyczna przy Dolnośląskiej Izbie Lekarskiej	Dr. Jacek Szepietowski Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
IRB Chair: Prof. dr hab. med. Włodzimierz Buczek Komisja Bioetyczna przy Okręgowej Izbie Lekarskiej w Białymstoku	Dr. Maria Poznanska Specderm Poznanska sp.j.
IRB Chair: Dr n. med. Włodzimierz Bednorz Komisja Bioetyczna przy	Dr. Jolanta Weglowska Derm Medica Sp.zo.o.
Belgium	
IRB Chair: Prof. dr.P.Michielsen Ethisch Comité UZA Drie Eikenstraat 655	Dr. Olivier Aerts University Hospital Antwerp
To the chair of the CEC	Dr. Pierre-Paul Roquet-Gravy Grand Hopital de Charleroi
N/A (no EC at this site)	Dr. Sven Lanssens Dermatologie Maldegem
To the chair of the CEC	Dr. Francisca Castelijns UZ Leuven
To the chair of the CEC	Dr. Christelle Scheers CHU Saint-Pierre
N/A (no EC at this site)	Dr. Erwin Suys Dermatologie Handelskaai
IRB Chair: Dr. Ingrid Martens Ethisch Comité -A.Z. St Lucas	Dr. Bernard Kint AZ Sint Lucas Ghent
Spain	
IRB Chair: Dr. Antonio López Pousa CEIm Fundacio de Gestio Sanitaria Hospital de la Santa Creu i Sant Pau	Dr. Esther Serra Baldrich Hospital Sant Pau i Santa Creu
	Dr. José Manuel Carrascosa Hospital Germans Trias i Pujol
	Dr. Pablo de la Cueva Dobao Hospita Universitario Infanta Leonor
	Dr. Rosa Izu Hospital Universitario Basurto
	Dr. Juan Francisco Silvestre Hospital General de Alicante
	Dr. Pablo Coto Segura Hospital Vital Álvarez Buylla
	Dr. Almudena Fernández Orland Hospital Virgen de La Macarena

Figure S1: HESD ≥ 4 -point reduction (weekly average) at Week 16 by disease severity subgroups for (A) itch and (B) pain among patients with ≥ 4 -points baseline itch/pain score in a pooled analysis of the DELTA 1 and DELTA 2

(A) Itch








Nominal $p \leq 0.01$, *Nominal $p < 0.001$.

For the composite estimand strategy, data were considered non-response after the initiation of the rescue treatment or after permanent discontinuation of treatment. Missing data were considered non-response. CI, confidence interval; HESD, Hand Eczema Symptom Diary; IGA-CHE, Investigator's Global Assessment for Chronic Hand Eczema; n, number of patients with baseline IGA-CHE score moderate or severe.

Figure S2: Reduction of HESD itch (A) and pain (B) scores (weekly average) of ≥ 4 points by week in patients with and without environmental trigger factors in a pooled analysis of DELTA 1 and DELTA 2



(B)




*Nominal $p \leq 0.05$, **Nominal $p \leq 0.01$, ***Nominal $p < 0.001$.

For the composite estimand strategy, data were considered non-response after the initiation of the rescue treatment or after permanent discontinuation of treatment. Missing data were considered non-response.

CI, confidence interval; HESD, Hand Eczema Symptom Diary; n, number of patients with baseline score ≥ 4 .

73 **Figure S3:** Reduction of HESD (A) itch and (B) pain scores (weekly average) of ≥ 4 points by week according to HECSI baseline
74 score in a pooled analysis of DELTA 1 and DELTA 2



75
76 *Nominal $p \leq 0.05$, **Nominal $p \leq 0.01$, ***Nominal $p < 0.001$.

77 For the composite estimand strategy data were considered non-response after the initiation of the rescue treatment or after permanent discontinuation of
78 treatment. Missing data were considered non-response.

79 CI, confidence interval; HECSI, Hand Eczema Severity Index; HESD, Hand Eczema Symptom Diary; n, number of patients with baseline score ≥ 4 .